Wockhardt Limited has launched the ‘Wockhardt Antibiotic Academy’, an initiative aimed at fostering scientific dialogue and collaboration to combat antimicrobial resistance (AMR). This platform will facilitate continuous medical education for healthcare professionals through knowledge exchange and real-world clinical experience. The academy seeks to promote evidence-based solutions and strengthen the fight against untreatable superbugs.
Wockhardt Launches Wockhardt Antibiotic Academy
Wockhardt Limited announced the launch of the “Wockhardt Antibiotic Academy”, a significant initiative dedicated to addressing the global threat of antimicrobial resistance (AMR). This new platform is designed as an open scientific learning environment for the registered medical fraternity across India.
Objective and Focus
The academy’s primary objective is to facilitate continuous medical education by enabling the exchange of knowledge, scientific discussions, and the sharing of real-world clinical experiences among healthcare professionals. It aims to foster a deeper understanding of drug resistance and promote evidence-based solutions to improve patient outcomes. The initiative underscores Wockhardt’s commitment to advancing the fight against AMR through collaboration and investment in scientific dialogue.
Addressing a Critical Healthcare Challenge
Antimicrobial resistance (AMR) is identified as one of the greatest threats to global public healthcare, with a significant number of deaths occurring annually due to multi-drug-resistant infections. The Wockhardt Antibiotic Academy serves as a platform to convene experts, enable dialogue, and invest in solutions that will help clinicians save patient lives. The company hopes this initiative will build a nationwide scientific movement to strengthen the fight against AMR.
About Wockhardt’s Drug Discovery Program
Wockhardt is a research-based global pharmaceutical and biotech company with a strong focus on unmet needs in anti-bacterial drugs. The company’s New Drug Discovery program has achieved significant milestones, including receiving USFDA QIDP Status for 6 of its anti-bacterial discovery programs. This highlights Wockhardt’s dedication to developing effective treatments against untreatable superbugs.
Source: BSE
